https://www.selleckchem.com/pr....oducts/abc294640.htm
Esophageal squamous cell cancer (ESCC) patients with the potentially resectable disease most would experience relapse after surgery. Immunotherapy has been reported to improve the prognosis of advanced esophageal cancer and may be a new strategy to prevent this urgent condition's recurrence. We first evaluated the efficacy and safety of neoadjuvant chemotherapy combined with immunotherapy in patients with resectable ESCC. All patients with resectable locally advanced ESCC (clinical stage III-IV. Received at least 1 cycle of neoadjuv
Curtir
Comentario
Compartilhar
